Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial.
Fiche publication
Date publication
septembre 2022
Journal
ESC heart failure
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Monzo L, Ferreira JP, Cleland JGF, Pellicori P, Mariottoni B, Hazebroek MR, Collier TJ, Cuthbert JJ, Pieske B, Petutschnigg J, Ahmed FZ, Girerd N, Clark AL, Cosmi F, Staessen JA, Heymans S, Rossignol P, Zannad F
Lien Pubmed
Résumé
In people at risk of heart failure (HF) enrolled in the Heart 'OMics' in AGEing (HOMAGE) trial, spironolactone reduced circulating markers of collagen synthesis, natriuretic peptides, and blood pressure and improved cardiac structure and function. In the present report, we explored factors associated with dyskalaemia.
Mots clés
Heart failure prevention, Hyperkalaemia, Hypokalaemia, Steroidal mineralocorticoid receptor antagonist
Référence
ESC Heart Fail. 2022 09 6;: